The 2-year benefit of bevacizumab in colorectal cancer may explain why survival benefits are seen in studies with two-year, ...

Findings from this survey also demonstrated that 23% of providers were comfortable with interpreting biomarker testing ...

Treosulfan plus fludarabine was approved by the FDA for children and adults with AML or MDS before allogenic hematopoietic ...

Aspirin reduced disease recurrence in patients PI3K-mutated colorectal cancer, underscoring the value of early genomic ...

The phase 3 RATIONALE-306 study found no significant difference in overall survival benefits from tislelizumab plus ...

Significant improvements in skin toxicity were observed by week 6 in all patients treated with HT-001 in the phase 2a ...

Five-year data shows lasting benefit for patients with advanced gastroesophageal cancers treated with nivolumab and chemotherapy.

Nivolumab plus chemotherapy improved long-term survival in Chinese patients with advanced gastric, GEJ, or esophageal cancer.

Patients receiving ponsegromab experienced significantly greater weight gain and physical activity than those receiving placebo. Ponsegromab (PF-06946860), a GDF-15 inhibitor, increased weight gain ...

22% of Community Providers Reported Biomarker Testing in Gastric/GEJ Cancers ...

Long-Term Survival Benefit Seen With Nivolumab Plus Chemo in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer ...

Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...